Recombinant IGF-1 Long R3 is an engineered structural analog of insulin-like growth factor 1 designed to overcome the rapid physiological clearance of the native peptide in laboratory models. This technical guide outlines the molecular modifications, receptor binding dynamics, extended half-life, and laboratory reconstitution protocols for researchers evaluating this compound.
Recombinant IGF-1 Long R3 is an engineered structural analog of insulin-like growth factor 1 designed to overcome the rapid physiological clearance of the native peptide in laboratory models. This technical guide outlines the molecular modifications, receptor binding dynamics, extended half-life, and laboratory reconstitution protocols for researchers evaluating this compound.
The igf 1 lr3 half life is estimated at approximately 20 to 30 hours in preclinical models, significantly exceeding the brief 20 to 30-minute half-life of native insulin-like growth factor 1. This extended duration of biological activity is primarily driven by a structural modification that dramatically reduces its binding affinity for endogenous IGF-binding proteins (IGFBPs), leaving a higher fraction of unbound peptide available to activate the IGF-1 receptor continuously.
In native biological systems, endogenous IGF-1 is rapidly sequestered by circulating IGFBPs (specifically IGFBP-3 and IGFBP-5), which modulate its bioactivity and target it for metabolic clearance. In contrast, the engineered sequence of recombinant IGF-1 Long R3 prevents high-affinity binding to these carrier proteins. As a result, when introduced into cell culture systems or animal models, the compound maintains an extended plasma and extracellular presence. This sustained pharmacodynamic profile eliminates the need for frequent repeat administration in longitudinal cell culture or preclinical studies, providing a highly predictable environment for quantitative measurement.
To understand why the r3 igf 1 variant exhibits such distinct pharmacokinetics, one must examine its primary sequence. Recombinant human IGF-1 Long R3 consists of 83 amino acids, compared to the 70-amino-acid chain of native human IGF-1. This extension includes a 13-amino-acid N-terminal extension (MFPAMPLSSLFVN) coupled with a critical single-amino-acid substitution: Glutamic acid at position 3 is replaced by Arginine (hence 'Arg3' or 'R3').
The substitution of Arginine at position 3 alters the electrostatic charge distribution across the N-terminal region of the peptide. Because the native Glutamic acid residue is essential for forming salt bridges with IGFBPs, replacing it with Arginine disrupts these ionic interactions. The additional 13-amino-acid extension further introduces steric hindrance, preventing IGFBPs from wrapping around the core domain of the peptide. Consequently, researchers evaluating lr3 igf observe receptor activation kinetics that are uncoupled from the regulatory inhibition typically exerted by binding proteins in physiological matrix assays.
When exploring how does igf-1 lr3 work in vitro, researchers focus on its interaction with the type 1 insulin-like growth factor receptor (IGF-1R), a transmembrane receptor tyrosine kinase. Despite its low affinity for binding proteins, recombinant igf-1 long r3 retains high affinity for the IGF-1R, binding to the extracellular alpha-subunits with equilibrium dissociation constants comparable to native IGF-1.
Upon ligand binding, IGF-1R undergoes autophosphorylation of key tyrosine residues within its intracellular beta-subunit domain. This activation triggers two primary intracellular signaling cascades: the Phosphoinositide 3-kinase (PI3K) / Akt pathway and the Mitogen-Activated Protein Kinase (MAPK) / ERK pathway. Preclinical studies suggest that sustained activation of the PI3K/Akt pathway downregulates pro-apoptotic factors like BAD and caspase-9 while upregulating downstream targets such as mammalian target of rapamycin complex 1 (mTORC1). Concurrently, activation of the MAPK pathway drives transcription factors involved in cellular proliferation, nuclear division, and cytoskeletal remodeling.
Within the broader landscape of growth factor research, structural variants are selected based on the specific kinetic requirements of the assay. Native IGF-1 features a rapid clearance rate due to its 20–30 minute half-life and strong affinity for IGFBPs, making it suitable for studies examining acute, physiological feedback loops. Conversely, IGF-1 DES lacks the N-terminal tripeptide (GPE), giving it exceptionally potent local receptor affinity but a very short systemic half-life, ideal for localized tissue perfusion studies.
In contrast, recombinant IGF-1 Long R3 provides an optimal balance of structural stability, extended systemic half-life (20–30 hours), and reduced protein binding. Researchers interested in broader endocrine cascades or pituitary axis secretagogues often evaluate this compound alongside growth hormone secretagogues like Ipamorelin or CJC-1295 DAC in comparative metabolic studies. Reviewing the full catalog of research peptides helps investigators choose the appropriate structural variant for their specific experimental design.
Modern igf1 lr3 research focuses heavily on cellular proliferation, tissue regeneration, and metabolic optimization in non-human experimental models. Because the peptide remains biologically active for extended durations, it serves as an efficient tool for studying myoblast differentiation, satellite cell activation, and extracellular matrix protein synthesis.
In rodent skeletal muscle cell models (such as C2C12 myoblasts), exposure to recombinant IGF-1 Long R3 accelerates the expression of myogenic regulatory factors, including MyoD and myogenin. In vitro data indicate that the sustained activation of IGF-1R by IGF-1 LR3 enhances glucose uptake and amino acid transport independent of ambient insulin concentration. Furthermore, preclinical investigations in cartilage and osseous tissue models evaluate its capacity to stimulate chondrocyte proliferation and type II collagen synthesis, providing key baseline data for tissue engineering frameworks.
To yield reproducible data in sensitive cell assays, research compounds must strictly meet identity, purity, and stability criteria. PX1 Research adheres to rigorous manufacturing and analytical protocols for all enterprise and academic clients sourcing compounds for wholesale research applications. Every lot of recombinant IGF-1 Long R3 undergoes exhaustive third-party analytical testing prior to release.
Purity is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a purity profile exceeding 98%. Molecular mass and amino acid sequence integrity are confirmed using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) or Electrospray Ionization Mass Spectrometry (ESI-MS). Furthermore, because bacterial contamination can alter cell viability assays, PX1 enforces strict endotoxin testing using Chromogenic Recombinant Factor C (rFC) or LAL assays to guarantee endotoxin levels below 0.01 EU/µg. All products are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day dispatch for orders placed Monday through Friday.
Proper handling and reconstitution of recombinant human proteins are critical to prevent denaturation, aggregation, or loss of bioactivity. Lyophilized recombinant IGF-1 Long R3 is stable at room temperature for short periods during transit, but should be stored at -20°C or -80°C upon receipt in a manual defrost-freezer for long-term storage.
For laboratory reconstitution, researchers typically dissolve the lyophilized powder in sterile 10mM–50mM acetic acid or 0.1M hydrochloric acid to achieve a concentration of 0.1–1.0 mg/mL, as acidic solutions prevent peptide aggregation. Once fully dissolved, the solution can be further diluted into aqueous buffers containing a carrier protein, such as 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA), or reconstituted using sterile bacteriostatic water depending on the assay protocol. Aliquots should be frozen at -20°C or lower to avoid repeated freeze-thaw cycles, which significantly compromise peptide integrity.
When designing in vitro assays utilizing IGF-1 LR3, researchers must account for the compound's enhanced potency relative to native growth factors. Due to the lack of IGFBP inhibition, effective working concentrations in serum-free culture media are often lower than those required for native IGF-1. Typical working concentrations in cell culture range from 1 ng/mL to 50 ng/mL depending on the cell line and target endpoint.
Researchers should also account for surface adsorption. Recombinant growth factors exhibit hydrophobic interactions that can cause them to adhere to standard polystyrene laboratory containers. Utilizing low-binding microplates and microcentrifuge tubes, alongside carrier protein supplementation (0.1% BSA), ensures accurate concentration control throughout prolonged incubation periods. For complete assay protocols and technical specifications, explore our comprehensive research hub.
What is the exact igf 1 lr3 half life in laboratory models?
Preclinical models indicate that the igf 1 lr3 half life is approximately 20 to 30 hours. This prolonged duration compared to native IGF-1 (20–30 minutes) is due to its reduced binding affinity for endogenous IGF-binding proteins (IGFBPs).
How does igf-1 lr3 work at the cellular level?
IGF-1 LR3 binds to the extracellular domain of the type 1 insulin-like growth factor receptor (IGF-1R), triggering receptor autophosphorylation. This activates downstream intracellular signaling cascades including the PI3K/Akt and MAPK/ERK pathways, driving cell proliferation, survival, and protein synthesis in vitro.
What makes recombinant igf-1 long r3 different from native IGF-1?
Recombinant igf-1 long r3 features an 83-amino-acid sequence containing a 13-amino-acid N-terminal extension and a Glutamic acid to Arginine substitution at position 3 (Arg3). These structural changes prevent high-affinity binding to IGFBPs, resulting in greater bioavailability and an extended biological half-life.
Why is r3 igf 1 favored over native proteins in cell culture assays?
Researchers favor r3 igf 1 in cell culture because native IGF-1 is rapidly inactivated or bound by carrier proteins secreted into the culture medium. IGF-1 LR3 remains free and active in solution, maintaining stable signaling over multi-day experimental timeframes.
What are the primary targets of igf1 lr3 research?
Primary areas of igf1 lr3 research include skeletal muscle satellite cell activation, myoblast differentiation, extracellular matrix protein production, cellular longevity assays, and cartilage tissue regeneration in animal and cell culture models.
How should lr3 igf be reconstituted for in vitro stability?
For maximum stability, lr3 igf should first be dissolved in a dilute acid solution (such as 10mM–50mM acetic acid) to an initial stock concentration before diluting into a buffer containing 0.1% BSA or sterile bacteriostatic water. Avoid repeated freeze-thaw cycles by storing single-use aliquots at -20°C or -80°C.
What analytical methods verify the purity of PX1 recombinant IGF-1 Long R3?
PX1 Research verifies compound identity and purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for >98% purity, Mass Spectrometry (MALDI-TOF/ESI-MS) for molecular mass confirmation, and chromogenic LAL assays to ensure endotoxin levels remain below 0.01 EU/µg.
How does IGF-1 LR3 compare to growth hormone secretagogues like Ipamorelin?
IGF-1 LR3 acts as a direct receptor agonist downstream of growth hormone signaling, directly activating the IGF-1R. Growth hormone secretagogues like Ipamorelin or CJC-1295 stimulate endogenous growth hormone secretion from pituitary cells upstream, relying on intact endocrine pathways.
Can recombinant IGF-1 Long R3 be supplied for commercial or institutional research?
Yes, PX1 Research supplies high-purity recombinant IGF-1 Long R3 for institutional, academic, and industrial laboratory applications. Bulk quantities and wholesale account options are available for qualified research organizations.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.